Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01409
|
|||||
| Drug Name |
Vildagliptin
|
|||||
| Synonyms |
Equa; Galvu; Galvus; Jalra; Xiliarx; Galvus (TN); Vidagliptin (see Vildagliptin); Vildagliptin (JAN/USAN/INN); (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile; (2S)-1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 1-[2-[(3-hydroxy-1-adamantyl)amino]acetyl]pyrrolidine-2-carbonitrile; 2-Pyrrolidinecarbonitrile, 1-[[(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)amino]acetyl]-, (2S)-(9CI)
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Type 2 diabetes [ICD11: 5A11] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C17H25N3O2
|
|||||
| Canonical SMILES |
C1CC(N(C1)C(=O)CNC23CC4CC(C2)CC(C4)(C3)O)C#N
|
|||||
| InChI |
InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
|
|||||
| InChIKey |
SYOKIDBDQMKNDQ-XWTIBIIYSA-N
|
|||||
| CAS Number |
CAS 274901-16-5
|
|||||
| Pharmaceutical Properties | Molecular Weight | 303.4 | Topological Polar Surface Area | 76.4 | ||
| Heavy Atom Count | 22 | Rotatable Bond Count | 3 | |||
| Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 4 | |||
| XLogP |
0.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
12015446
, 14849686
, 14898545
, 17194948
, 43529907
, 46512217
, 50459774
, 51091422
, 57371966
, 99443227
, 103381660
, 104178744
, 114788130
, 118314324
, 121147405
, 124772155
, 126651432
, 129307316
, 134358368
, 135683855
, 136375110
, 137004291
, 139563570
, 152037539
, 152159633
, 160967824
, 172085080
, 172914664
, 174477837
, 175266579
, 175426398
, 178102929
, 186021611
, 196105655
, 210275077
, 210280715
, 224646668
, 226406746
, 249810559
, 251883214
, 252032033
, 252160316
, 252216578
, 252308983
|
|||||
| ChEBI ID |
CHEBI:135285
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | National Center for Advancing Translational Science-Inxight: drug (I6B4B2U96P) | |||||
| 2 | Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.